Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc A...

Por Tran, Tram T., Mehta, Darshan, Mensa, Federico, Park, Caroline, Bao, Yanjun, Sanchez Gonzalez, Yuri
Publicado no Infect Dis Ther (2018)

Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older

Por Foster, Graham R., Asselah, Tarik, Kopecky-Bromberg, Sarah, Lei, Yang, Asatryan, Armen, Trinh, Roger, Zadeikis, Neddie, Mensa, Federico J.
Publicado no PLoS One (2019)

1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analys...

Por Rockstroh, Jurgen K, Bhagani, Sanjay R, Orkin, Chloe, Soto-Malave, Ruth, Lacombe, Karine, Zhang, Zhenzhen, Wang, Stanley, Mensa, Federico, Trinh, Roger
Publicado no Open Forum Infect Dis (2018)

Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects

Por Kosloski, Matthew P., Zhao, Weihan, Marbury, Thomas C., Preston, Richard A., Collins, Michael G., Pugatch, David, Mensa, Federico, Kort, Jens, Liu, Wei
Publicado no Antimicrob Agents Chemother (2018)

1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks

Por Sarrazin, Christoph, Tran, Tram, Dylla, Douglas, Feld, Jordan J, Arora, Sanjeev, Victor, David, Hu, Yiran B, Wang, Stanley, Mensa, Federico, Wyles, David L
Publicado no Open Forum Infect Dis (2018)

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir

Por Berger, Kristi L., Sarrazin, Christoph, Nelson, David R., Scherer, Joseph, Sha, Nanshi, Marquis, Martin, Côté-Martin, Alexandra, Vinisko, Richard, Stern, Jerry O., Mensa, Federico J., Kukolj, George
Publicado no PLoS One (2016)

Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials

Por Krishnan, Preethi, Pilot-Matias, Tami, Schnell, Gretja, Tripathi, Rakesh, Ng, Teresa I., Reisch, Thomas, Beyer, Jill, Dekhtyar, Tatyana, Irvin, Michelle, Xie, Wangang, Larsen, Lois, Mensa, Federico J., Collins, Christine
Publicado no Antimicrob Agents Chemother (2018)

HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection

Por Sarrazin, Christoph, Castelli, Francesco, Andreone, Pietro, Buti, Maria, Colombo, Massimo, Pol, Stanislas, Calinas, Filipe, Puoti, Massimo, Olveira, Antonio, Shiffman, Mitchell, Stern, Jerry O, Kukolj, George, Roehrle, Michael, Aslanyan, Stella, Deng, Qiqi, Vinisko, Richard, Mensa, Federico J, Nelson, David R
Publicado no Clin Exp Gastroenterol (2016)

Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection

Por Ng, Teresa I., Pilot-Matias, Tami, Tripathi, Rakesh, Schnell, Gretja, Krishnan, Preethi, Reisch, Thomas, Beyer, Jill, Dekhtyar, Tatyana, Irvin, Michelle, Lu, Liangjun, Asatryan, Armen, Campbell, Andrew, Yao, Betty, Lovell, Sandra, Mensa, Federico, Lawitz, Eric J., Kort, Jens, Collins, Christine
Publicado no Viruses (2018)

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment

Por Poordad, Fred, Felizarta, Franco, Asatryan, Armen, Sulkowski, Mark S., Reindollar, Robert W., Landis, Charles S., Gordon, Stuart C., Flamm, Steven L., Fried, Michael W., Bernstein, David E., Lin, Chih‐Wei, Liu, Ran, Lovell, Sandra S., Ng, Teresa I., Kort, Jens, Mensa, Federico J.
Publicado no Hepatology (2017)

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

Por Wyles, David, Poordad, Fred, Wang, Stanley, Alric, Laurent, Felizarta, Franco, Kwo, Paul Y., Maliakkal, Benedict, Agarwal, Kosh, Hassanein, Tarek, Weilert, Frank, Lee, Samuel S., Kort, Jens, Lovell, Sandra S., Liu, Ran, Lin, Chih‐Wei, Pilot‐Matias, Tami, Krishnan, Preethi, Mensa, Federico J.
Publicado no Hepatology (2018)

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection

Por Asselah, Tarik, Zeuzem, Stefan, Soriano, Vicente, Bronowicki, Jean-Pierre, Lohse, Ansgar W., Müllhaupt, Beat, Schuchmann, Marcus, Bourlière, Marc, Buti, Maria, Roberts, Stuart K., Gane, Edward J., Stern, Jerry O., Voss, Florian, Baum, Patrick, Gallivan, John-Paul, Böcher, Wulf O., Mensa, Federico J.
Publicado no PLoS One (2015)

Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis

Por Zeuzem, Stefan, Soriano, Vicente, Asselah, Tarik, Gane, Edward J., Bronowicki, Jean-Pierre, Angus, Peter, Lohse, Ansgar W., Stickel, Felix, Müllhaupt, Beat, Roberts, Stuart, Schuchmann, Marcus, Manns, Michael, Bourlière, Marc, Buti, Maria, Stern, Jerry O., Gallivan, John-Paul, Voss, Florian, Sabo, John P., Böcher, Wulf, Mensa, Federico J.
Publicado no Antimicrob Agents Chemother (2015)

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure

Por Poordad, Fred, Pol, Stanislas, Asatryan, Armen, Buti, Maria, Shaw, David, Hézode, Christophe, Felizarta, Franco, Reindollar, Robert W., Gordon, Stuart C., Pianko, Stephen, Fried, Michael W., Bernstein, David E., Gallant, Joel, Lin, Chih‐Wei, Lei, Yang, Ng, Teresa I., Krishnan, Preethi, Kopecky‐Bromberg, Sarah, Kort, Jens, Mensa, Federico J.
Publicado no Hepatology (2018)